Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 580Neoplasms 487Prostatic Neoplasms 311Lung Neoplasms 238Colorectal Neoplasms 201Motor Activity 131Carcinoma, Non-Small-Cell Lung 117Uterine Cervical Neoplasms 112Brain Neoplasms 110Pancreatic Neoplasms 108Head and Neck Neoplasms 106Stomach Neoplasms 99Carcinoma, Hepatocellular 99Rectal Neoplasms 97Ovarian Neoplasms 86Colonic Neoplasms 86Neoplasm Metastasis 67Multiple Myeloma 65Esophageal Neoplasms 65Hematologic Neoplasms 61Urinary Bladder Neoplasms 60Glioblastoma 59Melanoma 58Sarcoma 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Endometrial Neoplasms 56Glioma 53Lymphoma 50Leukemia, Myeloid, Acute 48Gastrointestinal Neoplasms 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Rubinstein-Taybi Syndrome × Clear all
NCT06740162 2026-02-23

PACE

University of North Carolina, Chapel Hill

Phase NA Recruiting
376 enrolled

Autism Spectrum Disorder, Trisomy 13 Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Down Syndrome, Fragile X Syndrome, Intellectual Disability, Motor Activity, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, WAGR Syndrome, Williams Syndrome, X-Linked Intellectual Disability, Neurodevelopmental Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡